Xen Matrix™ AB Surgical Graft in Ventral or Incisional Midline Hernias

NACompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
Incisional Hernia
Interventions
DEVICE

Xen Matrix AB

Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.

Trial Locations (11)

19104

Trustees of the University of Pennsylvania, Philadelphia

27710

Duke University Medical Center, Durham

30322

Emory University, Atlanta

43210

Ohio State University, Columbus

63108

Washington University, St Louis

79430

Texas Tech University Health Sciences Center, El Paso

90033

Keck Hospital of USC, Los Angeles

94107

California Pacific Medical Center - Sutter Health, San Francisco

97239

Oregon Health & Science University, Portland

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

C. R. Bard

INDUSTRY

NCT02691962 - Xen Matrix™ AB Surgical Graft in Ventral or Incisional Midline Hernias | Biotech Hunter | Biotech Hunter